Soleil Securities Reiterates a 'Buy' on Cephalon (CEPH)
More News related to CEPH
- Jefferies & Co Upgrades Cephalon (CEPH) to Buy
- Cephalon (CEPH) options active on flat volatility; shares sell off 7% on clinical trial
- Unusual 11 Mid-Day Movers 11/23: ABIO, SEED, FNET, CDTI Higher; NYNY, GGR, TTIL, PEET Lower
- RBC Downgrades Cephalon (CEPH) Following Cinquil Trial Results; Sees 'Little Momentum' Behind the Stock
- Baird Maintains a 'Neutral' Rating on Cephalon (CEPH), Reslizumab Mixed Results in EE Sets Back Potential for Upside
More News related to Analyst Comments
- Sprint Nextel (S) Completes Tender Offer for iPCS, Inc. (IPCS)
- Ford (F) and Geely Reportedly Clear Hurdle On Possible Volvo Deal
- Starent Networks (STAR) To Settle Shareholder Class Action Suit In Connection With Proposed Merger with Cisco (CSCO)
- Hurray! Holding (HRAY) To Acquire Ku6 in All Stock Transaction
Soleil Securities reiterates a 'Buy' on Cephalon (Nasdaq: CEPH), price target $92.
Soleil analyst says, "Yesterday CEPH reported above consensus Q3'2009 financial results (EPS of $1.62 vs. consensus of $1.41), and better than expected first-time 2010 guidance. Management provided diluted EPS guidance of $6.20 - $6.40, above our belief of a whisper number of $6.00 and official consensus of $6.22. We would also remind investors of management's long history of outperformance relative to official guidance...Though R&D will be up significantly year/year (up 15 - 20%) to $470-$490mm, it was still lower than the $500mm+ projection that we had heard rumored on the Street...Our model is under review as we update for newly issued guidance across the P&L, prescription trends, and current run rates."
To see more analyst ratings on CEPH Click Here.
Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas.
Related Categories
Analyst CommentsStocks Mentioned
-0.67Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
